 | • レポートコード：B-MOR-08031 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、麻酔薬の世界市場について調べ、麻酔薬の世界規模、市場動向、市場環境、薬剤タイプ別（全身麻酔、局所麻酔）分析、投与経路別（吸入、注射、その他）分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・麻酔薬の世界市場インサイト ・麻酔薬の世界市場環境 ・麻酔薬の世界市場動向 ・麻酔薬の世界市場規模 ・麻酔薬の世界市場規模：薬剤タイプ別（全身麻酔、局所麻酔） ・麻酔薬の世界市場規模：投与経路別（吸入、注射、その他） ・麻酔薬の世界市場規模：用途別 ・麻酔薬の世界市場：地域別市場規模・分析 ・麻酔薬の北米市場規模・予測 ・麻酔薬のアメリカ市場規模・予測 ・麻酔薬のヨーロッパ市場規模・予測 ・麻酔薬のアジア市場規模・予測 ・麻酔薬の日本市場規模・予測 ・麻酔薬の中国市場規模・予測 ・麻酔薬のインド市場規模・予測 ・麻酔薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global anesthesia drugs market is expected to register a CAGR of 3.5% during the forecast period (2018 – 2023). Anesthetic is a drug which causes anesthesia, it is a reversible loss of sensation. There are several types of anesthetic drugs available in the market, such as the general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia, etc.
Rise in the Number of Surgeries
According to the Center for Disease Control and Prevention (CDC), the total number of inpatient surgeries performed in the United States grew from 48 million in 2009 to 51.4 million in 2010, with cardiology, surgical, and obstetrical procedures being the most common ones. The number of surgeries being performed is rising every year. The overall increase in the number of surgeries performed has a strong impact on the anesthetics market, as anesthetic drugs are used in surgical procedures to reduce the pain during surgery. Along with rising surgeries, other factors such as new anesthetic drugs and reduction in the cost of newly invented drugs are also driving the market.
Side Effects of General Anesthesia
General anesthetic drugs cause several side effects including nausea, vomiting, dry mouth, sore throat, shivering, muscle aches, disorientation, itching, sleepiness, and mild hoarseness. More serious complications of the drug include delirium, cognitive dysfunction, and malignant hyperthermia. General anesthetic drugs can cause physiological changes, such as blood pressure variations which require a trained anesthesiologist to monitor the patient’s blood pressure levels continuously and to provide blood pressure medications if required. Carelessness or lack of knowledge of the anesthesiologist could pose potential risks. Hence, the side-effects of general anesthesia and patient’s reluctance towards using it, along with lack of skilled anesthetics and regulatory issues are restraining the market growth.
North America to dominate the Market
North America has the largest regional market share with revenue estimated to be over 32%. Some of the major driving forces that account for such growth in this region are the increase in a number of general and emergency surgeries, increase in cardiovascular and respiratory diseases, and rise in aging population. From the technology point of view, advancements in the development of new anesthesia drugs are a prime driving force of the market. Asia-Pacific was estimated to register the fastest CAGR through the forecast period (2018-2023).
Key Developments in the Market
• September 2017: AstraZeneca made an agreement with Aspen Global Incorporated (AGI).
• April 2017: B. Braun and Philips joined forces to innovate in ultrasound-guided regional anesthesia and vascular access.
Major Players: BAXTER HEALTHCARE, HOSPIRA, ABBOTT LABORATORIES, ASTRA ZENECA, ROCHE HOLDING AG, B. BRAUN MELSUNGEN AG, ABBVIE, BOEHRINGER INGELHEIM, EISAI, FRESENIUS SE & CO. KGAA, among others.
Reasons to Purchase this Report
• Current and future anesthesia drugs market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Identify the segment which is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Number of Surgeries
6.1.2 New Approvals of Anesthetic Drugs
6.1.3 Reduction in the Cost of Newly Invented Drugs
6.2 Market Restraints
6.2.1 Side-Effects of General Anesthetics
6.2.2 Lack of Skilled-Anesthetics
6.2.3 Regulatory Issues
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Drug Type
7.1.1 General Anesthesia Drugs
7.1.1.1 Propofol
7.1.1.2 Sevoflurane
7.1.1.3 Desflurane
7.1.1.4 Dexmedetomidine
7.1.1.5 Remifentanil
7.1.1.6 Midazolam
7.1.1.7 Others
7.1.2 Local Anesthesia Drugs
7.1.2.1 Injectable Anesthetics
7.1.2.2 Surface Anesthetics
7.2 By Route of Administration
7.2.1 Inhalation
7.2.2 Injection
7.2.3 Others
7.3 By Application
7.3.1 General surgeries
7.3.2 Plastic Surgery
7.3.3 Cosmetic surgeries
7.3.4 Dental surgeries
7.3.5 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Baxter Healthcare
9.2 Hospira
9.3 Abbott Laboratories
9.4 Astra Zeneca
9.5 Roche Holding AG
9.6 B. Braun Melsungen AG
9.7 AbbVie
9.8 Boehringer Ingelheim
9.9 Eisai
9.10 Fresenius SE & Co. KGaA
9.11 Others
*List not exhaustive
10. Future of the Market
11. Disclaimer